Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) EBIT (2017 - 2026)

Lexaria Bioscience's EBIT history spans 10 years, with the latest figure at -$1.5 million for Q1 2026.

  • Quarterly results put EBIT at -$1.5 million for Q1 2026, up 47.22% from a year ago — trailing twelve months through Feb 2026 was -$9.5 million (down 0.82% YoY), and the annual figure for FY2025 was -$11.9 million, down 106.51%.
  • EBIT for Q1 2026 was -$1.5 million at Lexaria Bioscience, up from -$1.6 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$668005.0 in Q1 2024 to a low of -$3.8 million in Q2 2025.
  • The 5-year median for EBIT is -$1.7 million (2022), against an average of -$1.9 million.
  • The sharpest move saw EBIT soared 49.53% in 2024, then crashed 311.83% in 2025.
  • Year by year, EBIT stood at -$1.7 million in 2022, then surged by 32.81% to -$1.1 million in 2023, then tumbled by 136.2% to -$2.7 million in 2024, then soared by 41.52% to -$1.6 million in 2025, then rose by 7.74% to -$1.5 million in 2026.
  • According to Business Quant data, EBIT over the past three periods came in at -$1.5 million, -$1.6 million, and -$2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.